Pain and multiple sclerosis: pathophysiology and treatment
- PMID: 23250765
- DOI: 10.1007/s11910-012-0320-5
Pain and multiple sclerosis: pathophysiology and treatment
Abstract
Pain is a common symptom in multiple sclerosis (MS) and has recently been estimated to be experienced by up to 75 % of patients. Pain can be present at any point in the course of the disease and patients may experience pain from various causes simultaneously. Pain in MS can also be secondary to other symptoms, such as spasticity, fatigue, and mood disorder. Of all drug use to treat MS symptoms, treatment for pain accounts for nearly 30 % of total use. At the same time, patients report low satisfaction with pain management. Pain affects quality of life and can influence a person's participation in family life and work and affect mood. Most of the pain literature in the field of MS is based on open-label studies involving small numbers of subjects. Placebo-controlled trials in severe pain syndromes such as trigeminal neuralgia are unethical but for other types of MS-related pain conditions, placebo-controlled trials are ethical and necessary to establish efficacy, particularly given the well-documented placebo effect for various painful conditions This review discusses available data and emphasizes areas of pain research that require further attention.
Similar articles
-
Management of pain in multiple sclerosis: a pharmacological approach.Nat Rev Neurol. 2011 Aug 16;7(9):519-27. doi: 10.1038/nrneurol.2011.120. Nat Rev Neurol. 2011. PMID: 21844896 Review.
-
An update on the pharmacological management of pain in patients with multiple sclerosis.Expert Opin Pharmacother. 2020 Dec;21(18):2249-2263. doi: 10.1080/14656566.2020.1757649. Epub 2020 Apr 28. Expert Opin Pharmacother. 2020. PMID: 32343626 Review.
-
Pharmacological management of pain in patients with multiple sclerosis.Drugs. 2010 Jul 9;70(10):1245-54. doi: 10.2165/11537930-000000000-00000. Drugs. 2010. PMID: 20568832 Review.
-
[Pain in multiple sclerosis: prevalence, mechanisms, types and treatment].Rev Neurol. 2010 Jan 16-31;50(2):101-8. Rev Neurol. 2010. PMID: 20112218 Review. Spanish.
-
Drugs treatment of pain in multiple sclerosis.Curr Clin Pharmacol. 2007 Sep;2(3):227-33. doi: 10.2174/157488407781668785. Curr Clin Pharmacol. 2007. PMID: 18690869 Review.
Cited by
-
Comprehensive Approach to Management of Multiple Sclerosis: Addressing Invisible Symptoms-A Narrative Review.Neurol Ther. 2021 Jun;10(1):75-98. doi: 10.1007/s40120-021-00239-2. Epub 2021 Apr 20. Neurol Ther. 2021. PMID: 33877583 Free PMC article. Review.
-
Neuropathic Pain in Neurologic Disorders: A Narrative Review.Cureus. 2022 Feb 20;14(2):e22419. doi: 10.7759/cureus.22419. eCollection 2022 Feb. Cureus. 2022. PMID: 35345699 Free PMC article. Review.
-
Revealing brain mechanisms of mTOR-mediated translational regulation: Implications for chronic pain.Neurobiol Pain. 2018 Mar 21;4:27-34. doi: 10.1016/j.ynpai.2018.03.002. eCollection 2018 Aug-Dec. Neurobiol Pain. 2018. PMID: 31194026 Free PMC article. Review.
-
Periorbital Nociception in a Progressive Multiple Sclerosis Mouse Model Is Dependent on TRPA1 Channel Activation.Pharmaceuticals (Basel). 2021 Aug 23;14(8):831. doi: 10.3390/ph14080831. Pharmaceuticals (Basel). 2021. PMID: 34451927 Free PMC article.
-
Inflammation triggers production of dimethylsphingosine from oligodendrocytes.Neuroscience. 2014 Oct 24;279:113-21. doi: 10.1016/j.neuroscience.2014.08.011. Epub 2014 Aug 21. Neuroscience. 2014. PMID: 25151189 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical